Exploratory Studies on RNAi-Based Therapies Targeting Angiotensinogen in Hypertension: Scoping Review.

Abstract

Background: Systemic arterial hypertension contributes to cardiovascular morbidity and mortality worldwide. Many patients cannot achieve optimal blood pressure (BP) control with traditional therapies, which often results in poor patient adherence and limited long-term efficacy. We investigated the potential of RNA interference (RNAi) therapies targeting hepatic angiotensinogen (AGT) for hypertension management. Methods: This scoping review was conducted by the Joanna Briggs Institute, following a six-stage methodological framework and adhering to PRISMA recommendations. A comprehensive search was conducted across seven databases to identify relevant studies published until May 2024. Data extraction was performed separately, and both quantitative and qualitative analyses were conducted. A population, concept, and context model-based search was performed, selecting controlled MeSH terms and uncontrolled descriptors and cross-referencing them using Booleans. Results: Fifteen articles met our inclusion criteria. Focusing on the efficacy and safety of RNAi-based therapies, this review discusses several key approaches, including antisense oligonucleotides (IONIS-AGT-LRx), small interfering RNA (siRNAs; zilebesiran), and adeno-associated viruses carrying short hairpin RNAs. Notably, zilebesiran conjugated with N-acetylgalactosamine significantly reduced systolic BP by 20 mmHg, sustained for up to six months post-administration, with minimal adverse effects. Conclusions: RNAi-based therapies, particularly those using siRNAs, such as zilebesiran, are promising for the treatment of hypertension. They offer long-term BP control with fewer doses, potentially improving patient adherence and outcome. Although these therapies address several limitations of current antihypertensive treatments, further studies are required to confirm their long-term safety and efficacy.